drugset / Trial / NCT01615809

Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia

NCT01615809

NaSingle-groupOpen-labelTreatment

Summary

The trial evaluates the overall tolerability of the drug and the efficacy of aerosolised amphotericin B as a lipid complex (ABLC) for primary prophylaxis of invasive pulmonary aspergillosis (IPA) in pediatric patients with acute leukemia undergoing intensive chemotherapy.

Timeline

Start
2011-10
Primary completion
2013-07
Completion
2013-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amphotericin B Unknown 25 mg Inhaled